Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lorlatinib + SHP099 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lorlatinib | Lorbrena | PF-06463922|Lorviqua | ALK Inhibitor 32 ROS1 Inhibitor 20 | Lorbrena (lorlatinib) is a small molecule inhibitor of Alk and Ros1 fusion proteins, which may result in suppression of Alk and Ros1-mediated signaling thereby inhibiting cell growth and causing tumor regression (PMID: 26144315). Lorbrena (lorlatinib) is FDA approved for use in patients with ALK-positive non-small cell lung cancer (FDA.gov). |
SHP099 | SHP-099|SHP 099 | SHP2 Inhibitor 20 | SHP099 is an allosteric inhibitor of SHP2 that stabilizes SHP2 in its autoinhibited conformation, which reduces downstream signaling and potentially leads to decreased growth of receptor tyrosine kinase-driven tumors (PMID: 27362227, PMID: 31043123). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK F1174L | neuroblastoma | sensitive | Lorlatinib + SHP099 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of SHP099 and Lorbrena (lorlatinib) decreased invasion and synergistically decreased viability of neuroblastoma cell lines harboring ALK F1174L in culture (PMID: 38032104). | 38032104 |
ALK R1275Q | neuroblastoma | sensitive | Lorlatinib + SHP099 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of SHP099 and Lorbrena (lorlatinib) synergistically decreased viability of neuroblastoma cell lines harboring ALK R1275Q in culture (PMID: 38032104). | 38032104 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|